FCA
FOLD

FinTrust Capital Advisors’s Amicus Therapeutics FOLD Stock Holding History

FinTrust Capital Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.57K Hold
147
– – ﹤0.01% 1241
2024
Q2 		$1.46K Hold
147
– – ﹤0.01% 1223
2024
Q1 		$1.73K Hold
147
– – ﹤0.01% 1121
2023
Q4 		$2.09K Hold
147
– – ﹤0.01% 1072
2023
Q3 		$1.79K Buy
+147
New +$1.9K ﹤0.01% 1037

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FinTrust Capital Advisors's FOLD Position: Q3 2024 in Review

FinTrust Capital Advisors held its Amicus Therapeutics (FOLD) position steady in Q3 2024 at 147 shares worth $1.57K. The position accounts for ﹤0.01% of the portfolio, ranked #1241.

FinTrust Capital Advisors first reported a position in FOLD in Q3 2023 and has held it in 5 quarters since. The position peaked at $2.09K in Q4 2023. 293 funds tracked by Wall St. Rank hold FOLD as of Q3 2024.

  • FinTrust Capital Advisors held 147 shares of Amicus Therapeutics worth $1.57K as of Q3 2024.
  • FinTrust Capital Advisors left its Amicus Therapeutics share count unchanged in Q3 2024.
  • Amicus Therapeutics made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1241 holding.
  • FinTrust Capital Advisors first reported a position in Amicus Therapeutics in Q3 2023 and has held it in 5 quarters since.
  • FinTrust Capital Advisors's Amicus Therapeutics position peaked at $2.09K in Q4 2023.
  • 293 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.